ZACKSยท2025-03-06 21:00Mergers and Acquisitions - Jazz Pharmaceuticals announced an agreement to acquire Chimerix for $8.55 per share, totaling nearly $935 million, reflecting a 72% premium based on Chimerix's closing price [2][3][4] - The acquisition will add Chimerix's lead pipeline drug, dordaviprone, to Jazz's portfolio, which is under FDA review for treating recurrent H3 K27M-mutant diffuse glioma, with a decision expected by August 18, 2025 [3][4] Regulatory Updates - GSK's biologics license application for depemokimab has been accepted by the FDA, seeking approval for asthma treatment and chronic rhinosinusitis with nasal polyps [7][8] - The target action date for GSK's application is December 16, 2025, based on positive trial data showing reduced exacerbation rates in asthma patients [9] Clinical Developments - Regeneron Pharmaceuticals received a positive opinion from the EMA's CHMP for linvoseltamab, aimed at treating relapsed and refractory multiple myeloma, with a final decision expected soon [11][12] - The FDA has also accepted the BLA for linvoseltamab, with a target action date of July 10, 2025 [13] Stock Performance - The Nasdaq Biotechnology Index increased by 2.62% over the past five trading sessions, while Moderna's shares rose by 4.85%, despite a 52.06% decline over the past six months [14] - Other notable stock performances include Gilead Sciences with a 46.55% increase over six months and Bristol-Myers Squibb with a 20.12% increase [14]